Gerresheimer announces profitable growth in 2023

Gerresheimer, a global provider of solutions for the pharmaceutical, biotechnology, and cosmetic industries, has reported positive financial results for the year 2023, marking an organic revenue growth of 10.4% and a substantial increase in its adjusted EBITDA of 17.5%. Based in Düsseldorf, Germany, the company saw its revenues reach 1.99 billion euros, up from 1.82 billion euros in 2022, and its adjusted EBITDA grow to 404.5 million euros.

Gerresheimer's strategy focused on innovation and customized solutions, particularly in the biopharmaceutical sectors, has enabled the company to improve its adjusted EBITDA margin to 20.8%. The high order backlog and the expansion of its production capacities internationally contribute to ensuring profitable growth for the future. Gerresheimer also foresees dynamic growth in the coming years, with forecasts for organic revenue growth and adjusted EBITDA.

The proposed dividend stands at 1.25 euros per share for the fiscal year 2023, reflecting management's confidence in Gerresheimer's continued strong performance. This proposal aligns with a distribution policy that remains at the top end of the 20 to 30% payout range.